IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Carcinoma, Squamous Cell of Head and Neck
M.D. Anderson Cancer Centermonoclonal_antibodyPhase 1/2Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 89/ 100
Competitive context
250 Active assets in the Carcinoma, Squamous Cell of Head and Neck cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Akeso | Phase 4 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Akeso | Phase 3 | BB |
Irinotecan Neonc Technologies, Inc. | Phase 2 | BB |
Capecitabine Merck Sharp & Dohme LLC | Phase 2 | BB |
Tisotumab Vedotin Seagen, a wholly owned subsidiary of Pfizer | Phase 2 | BB |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →